Denmark· DK-28106463520
Nimotop
A nimodipine product containing nimodipin, registered in Denmark by Orifarm A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Nimodipine is registered in 14 of 19 countries.
Countries holding a registration under ATC C08CA06 (nimodipine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Nimodipine · ATC C08CA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nimodipine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $5.28 in France to $7.99 in Switzerland — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nimodipine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.99
- FR France$5.28
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- NIMODIPIN
- Manufacturer
- Orifarm A/S
- Country
- Denmark (DK)
- ATC code
- C08CA06
- ATC class
- Nimodipine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106463520
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
202 interactions on record for nimodipine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nimodipine · interactions on record
202 records
- 15 severe
- 164 moderate
- 1 minor
- 20 info
Most severe, free to view
- DolasetronA04AA04severe
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C08CA06
Nimodipine, as other registers publish it.
- NorwayBrainalAristo Pharma
- CzechiaDILCERENZentiva, k.s., Praha
- DenmarkNimodipin "Paranova"Paranova Danmark ApS
- GermanyNimodipin CarinopharmCarinopharm Gmbh
- CzechiaNIMODIPIN CARINOPHARM
- GermanyNimodipin EthypharmAltan Pharmaceuticals S.A.
- GermanyNimodipin HexalHexal Ag
- United StatesnimodipineHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fde88ba7-f5d6-46b5-b74d-ac3f53e33555 GET /v1/drugs/fde88ba7-f5d6-46b5-b74d-ac3f53e33555?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "30 mg",
"auth_role": "DKMA",
"dk_drugid": "28106463520",
"substance": "NIMODIPIN",
"auth_procedure": "Par-Imp",
"in_medicinpriser": true,
"registration_date_serial": "44022"
}See everything about nimodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.